Progressive Supranuclear Palsy Pipeline Analysis report covers 8 drugs currently in different phases of development. Progressive Supranuclear Palsy or Steele-Richardson-Olszewski syndrome is a rare brain related disorder which affects body movement, eye movement, balance of the body. It is a FTD disorder associated with a decline in motor function and is similar to Parkinson’s disease. Symptoms include loss of balance, slurring of speech, abnormal eye movements and urinary incontinence. Imaging techniques such as Positron Emission Tomography (PET) scan and Magnetic Resonance Imaging (MRI) are used for the diagnosis of the disease.

The report provides PSP treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report are Abbvie Inc, Biogen and Cortice Biosciences among others.

Scope:

By Company
By Phase
By Molecule Type
By Region
By Route of Administration